Instem, a leading provider of software and services to the earlystage drug development healthcare market, has announced the acquisition of France-based Notocord, a profitable software business active in the pre-clinical Safety Pharmacology market. With a maximum consideration of €4.2m (£3.5m) the deal is relatively small, but is consistent with the group’s strategy of pre-clinical software market consolidation. We make modest upgrades to earnings forecasts (EPS +14% 2017E).
08 Sep 2016
Strategic step in Safety
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strategic step in Safety
- Published:
08 Sep 2016 -
Author:
Gareth Evans -
Pages:
4
Instem, a leading provider of software and services to the earlystage drug development healthcare market, has announced the acquisition of France-based Notocord, a profitable software business active in the pre-clinical Safety Pharmacology market. With a maximum consideration of €4.2m (£3.5m) the deal is relatively small, but is consistent with the group’s strategy of pre-clinical software market consolidation. We make modest upgrades to earnings forecasts (EPS +14% 2017E).